# 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Source: https://onco.cc/trials/nct06592326/  
OnCo record `nct06592326` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Toripalimab, Gemcitabine, Carboplatin and Cisplatin in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT06592326 by Mabwell (Shanghai) Bioscience Co., Ltd., with 460 participants planned, started 2024-08-22 and due to reach its primary completion in 2027-09. Interventions recorded: 9MW2821, Toripalimab, Gemcitabine and Cisplatin/Carboplatin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06592326
- Phase: 3
- Setting: A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 460

## Sources

- ClinicalTrials.gov NCT06592326: https://clinicaltrials.gov/study/NCT06592326

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06592326.json